U.S. IPO Weekly Recap: A Quiet Week Ahead Of 2018's Final Stretch

Dec. 01, 2018 12:12 PM ETMRNA

No companies went public this past week, during the post-Thanksgiving lull.

Three healthcare deals joined the IPO calendar for next week. Messenger RNA developer Moderna (MRNA) is the week's largest offering, aiming to raise $500 million in the biggest biotech IPO ever.

There were no new IPO filings, aside from two SPACs. Blank check company Andina Acquisition III (ANDAU) filed to raise $100 million to acquire a business in Latin America, while Chardan Healthcare Acquisition (CHACU) filed to raise $70 million as it explores a healthcare business to acquire. Therefore, what is currently in the IPO pipeline is what can go public in 2018; others will have to wait.

The IPO Index climbed 4.0% this past week, though it is still well below its level before the sell-off that began in October.

2 SPAC Filings During the Week of November 26th, 2018





Andina Acquisition III (ANDAU)




Blank check company formed to acquire a business in Latin America.

Chardan Healthcare Acq. (CHACU)




Blank check company formed by Chardan to acquire a healthcare business.

Editor's Note: This article covers one or more microcap stocks. Please be aware of the risks associated with these stocks.

This article was written by

Renaissance Capital provides pre-IPO research to institutional investors and investment banks. The Firm manages two IPO-focused funds: The Renaissance IPO ETF (NYSE: IPO) and the Renaissance International IPO ETF (NYSE: IPOS). Individual investors can get a free overview of the IPO market on www.renaissancecapital.com, and try a free trial of our premium platform, IPO Pro (ipopro.renaissancecapital.com). Through Renaissance Capital’s pre-IPO research service, institutional investors get an independent opinion, in-depth fundamental analysis, and customizable financial models on all IPOs.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.